FDA-approved drugs that also permeated across the BBB potentially included Selumetinib, used for the treatment of neurofibromatosis type 1 (NF1) with positive correlation with the control group, and Lenvatinib, a KIT, PDGFR, FGRG, and VEGFR inhibitor (FGFR1, KIT, FLT4, FLT1, KDR), with a negative correlation with the control group (Figure 6D) (41,42). This evidence concerns the gene FGFR1 and neurofibromatosis type 1.